CAR T-Cell therapy

CAR (Chimeric Antigen Receptor) T-cell therapy is an emerging form of cancer immunotherapy that uses your body’s own immune system to recognize and destroy cancer cells with minimal damage to healthy cells.

If at least two other kinds of treatments have failed, ask your provider if CAR T-cell therapy is right for you based on your type of cancer.

CAR T cells are created by collecting your own white blood cells (through a process called “leukapheresis”), isolating the T cells, then modifying them by adding the CAR gene. Your new CAR T cells are added back into your bloodstream during a one-time infusion. You will need three days of chemotherapy to prepare your body for the infusion.

Your provider will order blood tests to monitor your progress as well as any potential side effects following the infusion.

Side effects can be significant, but are typically manageable and resolve in most patients. Talk with your provider. Side effects may include but are not limited to the following: 

• Low blood counts from the conditioning chemotherapy 
• Cytokine release syndrome (CRS) which may include fever, fast heart rate, low blood pressure and low blood oxygen 
• Neurological effects including confusion, tremor or difficulty speaking

Everyone’s coverage is different. We have dedicated financial counselors who can help you navigate the insurance and financial side of treatment, and evaluate your options.

Early trials for this type of immune therapy have found high success rates. In a clinical study of patients with non-Hodgkin lymphoma who had failed other treatments, the treatment was shown to help 51% (52 out of 101) achieve complete remission, and 21% (22 out of 101) achieved a partial remission. People generally responded to treatment within 1 month (range: 0.8-6.2 months). For those who achieved a complete remission, the response is generally ongoing.